Proposed Idea | iConquerMS.org

These ideas have been proposed by the community but no analysis has been initiated.

How many people on Tysabri experience a waning effect as they approach their next dose? How much does this effect impact their symptoms and quality of life?

Are people with MS who received the Johnson & Johnson Covid 19 vaccine and got blood clots due to it more susceptible to getting blood clots in the future?

What is the impact of continuing or stopping DMTs in people with MS who are over the age of 65?

How is a person with MS affected by having Covid-19 more than once?

More data/experience on ‘wearing off phenomenon’ with Ocrevus treatment. Can next infusion be administered at 5 months instead of 6 months to avoid this wearing off phenomenon?

For the 5-25 percent of MS patients who do not experience fatigue as a major symptom, is there a protective factor to be learned? Could we understand why they do not report having the most common symptom?

Do some MS patients who are/have taken Ocrevus have advancing disability when compared to other medications. In particular gait and mobility issues.

I would like to know whether IV Nutrient Therapy could help manage MS symptoms and prevent future disease activity.

How are patients living with both MS and other autoimmune diseases managing symptoms, medications and their medical team?

Do people with MS get long Covid more often than those without MS?

first
previous
1
2
3
4
5
6
7
8
9
…
next
last